A New Complex Design of Fe (II) Isoleucine Dithiocarbamate as a Novel Anticancer and Antivirus against SARSCOV-2 (COVID-19)

This study was carried out to synthesize a new complex of Fe(II) with isoleucine dithiocarbamate
ligand and to determine its potential as an anticancer and antiviral agent for SARSCOV-2. Methods: The synthesized
complexes were then characterized by UV-vis and FT-IR spectroscopy and their melting points. The value of the
conductivity of the complex compound is also determined. Anti-cancer activity was tested in vitro and molecular
docking. Its potential as an antiviral against SARSCOV-2 was also carried out by molecular docking. Pharmacokinetics/
ADMET properties were also carried out on the complex. Result: Spectral results showed the successful synthesis of
Fe(II) isoleucine dithiocarbamate complex. The complex produced UV-vis spectra at 268 and 575 nm, and the IR data
at 399–599 cm-1 showed the coordination between the Fe(II) atoms with sulphur, nitrogen and oxygen of the isoleucine
dithiocarbamate ligand. Fe(II) isoleucine dithiocarbamate had a cytotoxicity effect on the MCF-7 cell line (IC50
=613
µg/mL). The complex significantly caused morphological changes in the breast cancer cell line, finally leading to cell
apoptosis. Conclusion: Cytotoxic test of Fe(II) isoleucine dithiocarbamate showed moderate anticancer activity on
MCF-7 cancer cells and showed antiviral activity against SARSCOV-2 by interfering with spike glycoprotein –ACE2
receptors, and inhibiting major proteases and 3Clpro